Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00YSJ
|
|||
| Former ID |
DCL000313
|
|||
| Drug Name |
Tecadenoson
|
|||
| Synonyms |
CVT-510; 204512-90-3; UNII-GZ1X96601Z; CHEMBL392149; GZ1X96601Z; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol; BDBM50224766; Tecadenoson [USAN:INN]; Tecadenoson (USAN/INN); AC1L4KMO; SCHEMBL246787; GTPL5592; CHEMBL356254; DTXSID80174415; BDBM50138530; DB04954; N6-[3-(R)-tetrahydrofuranyl]adenosine; HY-19661; Adenosine, N-(3R)-tetrahydro-3-furanyl-; LS-190860; Adenosine, N-(3R)-tetrahydro-3-furanyl)-; CS-0016174; D06019; CVT-510; N-(3-Tetrahydrofuranyl)-6-aminopurine riboside; Selenocompounds
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atrial fibrillation [ICD-11: BC81.3; ICD-10: I48] | Discontinued in Phase 3 | [1], [2] | |
| Cardiac arrhythmias [ICD-11: BC9Z] | Discontinued in Phase 3 | [1], [2] | ||
| Company |
CV Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H19N5O5
|
|||
| Canonical SMILES |
C1COCC1NC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O
|
|||
| InChI |
1S/C14H19N5O5/c20-3-8-10(21)11(22)14(24-8)19-6-17-9-12(15-5-16-13(9)19)18-7-1-2-23-4-7/h5-8,10-11,14,20-22H,1-4H2,(H,15,16,18)/t7-,8-,10-,11-,14-/m1/s1
|
|||
| InChIKey |
OESBDSFYJMDRJY-BAYCTPFLSA-N
|
|||
| CAS Number |
CAS 204512-90-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Agonist | [3], [4] |
| Protein kinase C (PRKC) | Target Info | Binder | [5] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5592). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010504) | |||
| REF 3 | CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009. | |||
| REF 4 | Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc Toxicol. 2003;3(1):71-88. | |||
| REF 5 | Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.